Here are five things to know:
1. Maryland’s Stem Cell Research Fund is designed to accelerate research and commercialization of stem cell therapies. To date, the fund has committed more than $147 million to over 430 research projects.
2. All sponsored projects must involve human stem cells and be conducted in Maryland.
3. The two awards totaled around $530,000.
4. CEO of Gemstone Biotherapeutics Emily English, PhD, received a commercialization award of $299,998. This award is intended to help with the creation of startup companies or new technologies developed in Maryland-based firms.
5. Sharon Gerecht, PhD, of Baltimore-based Johns Hopkins University received a $230,000 validation award, which is intended to help transition promising stem cell technologies with commercial potential from universities and research labs to the commercial sector.
More articles on biologics:
5 things to know about the global orthobiologics market
Kuros Biosciences appoints 5 spine surgeons to advisory board
Orthopedic surgeon named Reinvent Biologics’ CMO: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
